01—Abstract
Summary
Summary of the 8-K filed February 11, 2026. Cited figures are marked; the original filing is the authoritative source.
On February 10, 2026, Cencora priced a $3.0 billiona senior unsecured notes offering in five tranches: $500 million of 3.950% notes due 2029, $500 million of 4.250% notes due 2030, $500 million of 4.600% notes due 2033, $1.0 billion of 4.900% notes due 2036, and $500 million of 5.650% notes due 2056.
The offering is expected to close February 13, 2026, and yield estimated net proceeds of about $2.98 billionb. Based on the disclosed coupons, the weighted average coupon is roughly 4.71%. The proceeds will primarily repay the $3.0 billion 364-Day Term Loan Facility entered into January 12, 2026.
That facility funded a portion of Cencora's acquisition of OneOncology. Refinancing the short-term bridge-style debt into longer-dated fixed-rate notes (maturities from 2029 to 2056) reduces near-term refinancing risk and replaces floating or short-term funding with term debt. Any remaining proceeds would go to general corporate purposes.
The filing does not quantify the acquisition's purchase price or the resulting change in leverage, so investors should review the company's upcoming periodic filings for those details. The offering was made under a Form S-3 shelf registration filed November 26, 2024.
The filing also discloses that several underwriters and their affiliates hold roles in Cencora's revolving credit facility, commercial paper program, receivables securitization facility, term loan facilities, and the 364-Day Term Loan Facility, and that U.S. Bancorp Investments is an affiliate of the notes trustee. As of December 31, 2025, commercial paper borrowings were $220.0 millionc and the receivables securitization facility had no borrowings outstanding.
02—Key points
Key Highlights
- Cencora priced $3.0 billion of senior unsecured notes across five tranches, with maturities from 2029 to 2056 and coupons from 3.950% to 5.650%.
- Estimated net proceeds are approximately $2.98 billion, with closing expected February 13, 2026, subject to customary conditions.
- Proceeds will primarily repay the $3.0 billion 364-Day Term Loan Facility, which funded part of the OneOncology acquisition.
- The weighted average coupon across the offering is approximately 4.71%, calculated from the disclosed tranche sizes and coupons.
- The $1.0 billion 2036 tranche is the largest; the 2056 tranche carries the highest coupon at 5.650% and extends the maturity profile to 30 years.
- The notes are senior unsecured obligations issued under the Form S-3 shelf (No. 333-283481) filed November 26, 2024.
- Several underwriters and affiliates also hold roles in Cencora's credit facilities and commercial paper program, which is a potential conflict-of-interest disclosure.
03—Questions
Frequently Asked Questions
Why is Cencora issuing $3 billion of notes now?
The company is using the proceeds to repay the $3.0 billion 364-Day Term Loan Facility entered into January 12, 2026, which financed part of its acquisition of OneOncology. Termed-out senior notes replace short-term acquisition financing with longer-dated fixed-rate debt.
What are the terms and maturities of the notes?
The offering includes $500 million of 3.950% notes due February 13, 2029; $500 million of 4.250% notes due November 15, 2030; $500 million of 4.600% notes due February 13, 2033; $1.0 billion of 4.900% notes due February 13, 2036; and $500 million of 5.650% notes due February 13, 2056. All are senior unsecured obligations.
How much cash will Cencora actually receive, and when does the deal close?
Cencora estimates net proceeds of approximately $2.98 billion after the underwriting discount and offering expenses. Closing is expected February 13, 2026, subject to customary closing conditions.
Does this offering change Cencora's near-term liquidity or refinancing risk?
Yes, it should reduce near-term refinancing risk. The 364-day bridge-style loan, which matures within a year, is being replaced with notes maturing from 2029 to 2056. The filing does not disclose pro forma leverage, so the net effect on the balance sheet is not quantified here.
Are there any conflicts of interest or related relationships with the underwriters?
The filing discloses that Citigroup, J.P. Morgan, BofA Securities, Wells Fargo Securities, and their affiliates have served as underwriters on past Cencora note offerings and hold roles in its revolving credit facility, commercial paper program, term loans, and the 364-Day Term Loan Facility. U.S. Bancorp Investments, an underwriter, is an affiliate of the notes trustee. These are typical ongoing relationships, but investors may wish to note them.
04—Continue